Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk Less Frequent Natalizumab Dosing Dramatically Reduces PML Risk

Extended-interval dosing of natalizumab was associated with a 94% lower risk for progressive multifocal leukoencephalopathy vs standard dosing in patients with MS positive for anti-JC virus antibody.Medscape Medical News

Source: Medscape Medical News Headlines - February 3, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news